558 related articles for article (PubMed ID: 14642971)
1. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
[TBL] [Abstract][Full Text] [Related]
2. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U
Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
[TBL] [Abstract][Full Text] [Related]
3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
4. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
5. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.
Javitt DC
Curr Opin Psychiatry; 2006 Mar; 19(2):151-7. PubMed ID: 16612195
[TBL] [Abstract][Full Text] [Related]
6. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
Hashimoto K; Iyo M
Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
[TBL] [Abstract][Full Text] [Related]
7. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
8. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
9. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders.
Wang SJ; Yang TT
Drug News Perspect; 2005 Nov; 18(9):561-6. PubMed ID: 16421629
[TBL] [Abstract][Full Text] [Related]
10. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
11. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs.
Fumagalli F; Frasca A; Racagni G; Riva MA
Mol Pharmacol; 2008 May; 73(5):1484-90. PubMed ID: 18250147
[TBL] [Abstract][Full Text] [Related]
12. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
Gosselin O; Ribeyre JM; Kahn JP
Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
[TBL] [Abstract][Full Text] [Related]
13. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia.
Heresco-Levy U; Silipo G; Javitt DC
Psychopharmacol Bull; 1996; 32(4):731-40. PubMed ID: 8993096
[TBL] [Abstract][Full Text] [Related]
14. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller N
Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
[TBL] [Abstract][Full Text] [Related]
16. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
Del'guidice T; Beaulieu JM
Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
[TBL] [Abstract][Full Text] [Related]
17. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
18. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
19. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.
Javitt DC; Duncan L; Balla A; Sershen H
Mol Psychiatry; 2005 Mar; 10(3):275-87. PubMed ID: 15278098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
